Given the emerging evidence that missense substitutions in protein-binding domains of PALB2 are connected with disease predisposition, we aimed to elucidate whether cancer-associated missense mutations may also perturb the function of the PALB2 ChAM. This evidence concerns the gene PALB2 and cancer.